Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations - Takeaways - MDSpire

Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations

  • By

  • Federica Attaianese

  • Giulia Carreras

  • Sandra Trapani

  • Ilaria Alberti

  • Maurizio Aricò

  • Marina Attanasi

  • Giulia Bertolucci

  • Silvia Bressan

  • Désirée Caselli

  • Veronica Casotto

  • Salvatore Cazzato

  • Francesco Chiarelli

  • Enrico Felici

  • Anna Frusciante

  • Maria Antonia Galeone

  • Silvia Garazzino

  • Antonietta Giannattasio

  • Eloisa Gitto

  • Antonio Guerriero

  • Fiorentina Guida

  • Giovanna Iudica

  • Marcello Lanari

  • Claudia Mandato

  • Alice Manzini

  • Gaia Martelli

  • Gregorio Paolo Milani

  • Maria Moriondo

  • Lucia Dora Notarangelo

  • Felice Nunziata

  • Roberta Pellegrino

  • Diego Peroni

  • Emanuela Piccotti

  • Eduardo Ponticiello

  • Silvia Ricci

  • Immacolata Rulli

  • Fabio Savoia

  • Erika Silvestro

  • Antonella Sisto

  • Federica Soro

  • Stefania Tonetto

  • Alessandro Zago

  • Carlo Dani

  • Chiara Azzari

  • Giuseppe Indolfi

  • July 1, 2026

  • 0 min

Share

  • 1

    Respiratory syncytial virus (RSV) is a leading cause of lower respiratory infections and pediatric hospital admissions globally.

  • 2

    Nirsevimab is a long-acting monoclonal antibody that offers single-dose seasonal protection against RSV for all infants.

  • 3

    The study evaluated the real-world cost-effectiveness of nirsevimab in preventing RSV-associated hospitalizations across 19 Italian pediatric hospitals.

  • 4

    Data were collected from October 2022 to March 2025, excluding the COVID-19 pandemic period to avoid distortion of baseline estimates.

  • 5

    Cost-effectiveness was assessed by comparing hospitalization rates and costs between nirsevimab immunization and a no-immunization scenario.

Original Source(s)

Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations

  • by Federica Attaianese, Giulia Carreras, Sandra Trapani, Ilaria Alberti, Maurizio Aricò, Marina Attanasi, Giulia Bertolucci, Silvia Bressan, Désirée Caselli, Veronica Casotto, Salvatore Cazzato, Francesco Chiarelli, Enrico Felici, Anna Frusciante, Maria Antonia Galeone, Silvia Garazzino, Antonietta Giannattasio, Eloisa Gitto, Antonio Guerriero, Fiorentina Guida, Giovanna Iudica, Marcello Lanari, Claudia Mandato, Alice Manzini, Gaia Martelli, Gregorio Paolo Milani, Maria Moriondo, Lucia Dora Notarangelo, Felice Nunziata, Roberta Pellegrino, Diego Peroni, Emanuela Piccotti, Eduardo Ponticiello, Silvia Ricci, Immacolata Rulli, Fabio Savoia, Erika Silvestro, Antonella Sisto, Federica Soro, Stefania Tonetto, Alessandro Zago, Carlo Dani, Chiara Azzari, Giuseppe Indolfi

  • July 1, 2026

Related Content

Modified-release hydrocortisone (Efmody®) in children with congenital adrenal hyperplasia: a retrospective registry study

Single-center experience of interventional therapy for congenital portal-systemic shunt in children

Pelvic osseous foreign body identified during laparoscopic appendectomy in a child with acute appendicitis: a case report